Regulatory Moderna flu vaccine wins unanimous support from FDA panel BioPharma DiveThe endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioPharma Dive The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year. Infectious Disease Read full story Post navigation Previous: MSD takes on Pfizer’s Prevnar with new Capvaxive approvalNext: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026